Managing rhinitis: Strategies for improved patient outcomes

Allergy and Asthma Proceedings

Volumn 29, Issue 4, 2008, Pages 349-357

  Carr, Warner W ^{a,d,e,f,g,h,i}   Nelson, Michael R ^b   Hadley, James A ^c,d,e,g,h  

^a Allergy & Asthma Associates of Southern California   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d Meda Pharmaceuticals Inc

^e Alcon ^*

^f ASTRAZENECA   (United Kingdom)

^g GLAXOSMITHKLINE   (United Kingdom)

^h Sanofi Aventis

ⁱ TEVA Pharmaceuticals   (Hungary)

Author keywords

Allergens; Allergic rhinitis; Anticholinergics; Antihistamines; Congestion; Decongestants; Immunotherapy; Intranasal corticosteroids; Nonallergic rhinitis; Vasomotor rhinitis

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHROMONE DERIVATIVE; CORTICOSTEROID; DECONGESTIVE AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

COMORBIDITY; CONFERENCE PAPER; DESENSITIZATION; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; HAY FEVER; HUMAN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERENNIAL RHINITIS; RHINITIS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; CHOLINERGIC ANTAGONISTS; CHROMONES; COMORBIDITY; DESENSITIZATION, IMMUNOLOGIC; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HISTAMINE ANTAGONISTS; HUMANS; LEUKOTRIENE ANTAGONISTS; NASAL DECONGESTANTS; PATIENT COMPLIANCE; PATIENT SATISFACTION; RHINITIS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 50249099795     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2008.29.3145     Document Type: Conference Paper

References (61)

1. Allergies in America: A landmark survey of nasal allergy sufferers. Available on-line at www.myallergiesinamerica.com; last accessed January 29, 2008.
2. Management of allergic rhinitis in the working-age population. Evidence Report/Technology Assessment, Number 67. Agency for Healthcare Research and Quality, No. 03-E013, January 2003.
3. American Academy of Allergy, Asthma, and Immunology. Overview of allergic diseases. In The Allergy Report, vol 1. Available on-line at www.aaaai.org/ar/volumel.pdf; last accessed January 17, 2008.
4. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 28:3-9, 2007.
5. Greiner AN, and Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol 118:985-998, 2006.
6. Greiner AN. Allergic rhinitis: Impact of the disease and considerations for management. Med Clin North Am 90:17-38, 2006.
7. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81:478-518, 1998.
8. Nassef M, Shapiro G, and Casale TB. Identifying and managing rhinitis and its subtypes: Allergic and nonallergic components - A consensus report and materials from the Respiratory and Allergic Disease Foundation. Curr Med Res Opin 22:2541-2548, 2006.
9. Schatz M, Leung DYM, Goldstein S, et al. Consultation and referral guidelines citing the evidence: How the allergist-immunologist can help. J Allergy Clin Immunol 117:S495-S523, 2006.
10. Ciprandi G. Treatment of nonallergic perennial rhinitis. Allergy 59:16-23, 2004.
11. Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 22:185-189, 2001.
12. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 99:S773-S780, 1997.
13. Leynaert B, Neukirch C, Liard R, et al. Quality of life in allergic rhinitis and asthma. Am J Respir Crit Care Med 162:1391-1396, 2000.
14. Corren J. Allergic rhinitis and asthma: How important is the link? J Allergy Clin Immunol 99:S781-S786, 1997.
15. Van Cauwenberge P, Bachert C, Passalaqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 55:116-134, 2000.
16. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. ARIA Workshop Report. J Allergy Clin Immunol 108S147-S334, 2001.
17. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma, and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol. In preparation.
18. The University of Nottingham. The pharmacology and biochemistry of histamine receptors. Available on-line at www.nottingham.ac.uk/∼mqzwww/ histamine.html; last accessed January 8, 2008.
19. Simon FER. Advances in H1-antihistamines. N Engl J Med 351:2203-2217, 2004.
20. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma (ARIA). In collaboration with the World Health Organization. Executive Summary of the Workshop Report. Allergy 57:841-855, 2002.
21. Simons KI, and Simons PE. H1-receptor antagonists: Pharmacokinetics and clinical pharmacology. In Histamine and H1-receptor antagonists in allergic diseases. Simons FER (ed.). New York: Marcel Dekker, 1996. 175-213.
22. Hindmarch I, Shamsi Z, and Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: A double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 32:133-139, 2002.
23. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 105:S622-S627, 2000.
24. Mann RD, Pearce GL, Dunn N, et al. Sedation with "nonsedating" antihistamines: Four prescription-event monitoring studies in general practice. BMJ 320:1184-1187, 2000.
25. Nicholson AN, Stone BM, Turner C, et al. Antihistamines and aircrew: Usefulness of fexofenadine. Aviation Space Environ Med 71:2-6, 2000.
26. Corren J, Storms W, Bernstein J, et al. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 27:543-553, 2005.
27. Bernstein JA. Azelastine hydrochloride: A review of pharmacology, pharmacokinetics, clinical efficacy, and tolerability. Curr Med Res Opin 23:2441-2452, 2007.
28. Banov CH, and Lieberman P. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol 86:28-35, 2001.
29. Kaliner MA. A novel and effective approach to treating rhinitis with nasal antihistamines. Ann Allergy Asthma Immunol 99:383-390, 2007.
30. Astelin (azelastine) prescribing information. Physicians' Desk Reference. Montvale, NJ: Thomson, Inc., 2007.
31. Patel P, D'Andrea C, and Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol 21:499-503, 2007.
32. Berger WE, White MV. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 91:205-211, 2003.
33. La Force C, Corren J, Wheeler WJ, et al. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol 93:154-159, 2004.
34. Berger W, Hampel F, Bernstein J, et al. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 97:375-381, 2006.
35. Sacks H. Sensory study of a new formulation of azelastine nasal spray with reduced bitterness. Poster presented at the 46th Annual Scientific Session of the Western Society of Allergy, Asthma and Immunology, January 21-25, 2008. Kailua-Kona, Hawaii. Data on file, Meda Pharmaceuticals Inc., Somerset, NJ, 2008.
36. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: Olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 28:592-599, 2007.
37. Poole JA, O'Relley C, Rosenwasser LJ. Olopatadine and Patanol effect TNF-α and IL-1β production in LPS-activated peripheral blood monocytes. J Allergy Clin Immunol 115:S49, 2005.
38. Moyer P. Ciclesonide is effective long-term in perennial allergic rhinitis: Presented at AAAAI. Available on-line at www.docguide .com/news/content.nsf/news/852571020057CCF68525729C0046 DBF9; last accessed January 9, 2008.
39. Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 98:12-21, 2007.
40. Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: A comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol 21:70-79, 2007.
41. Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 136:S107-S124, 2007.
42. Blaiss MS, Benninger MS, Fromer L, et al. Expanding choices in intranasal steroid therapy: Summary of a roundtable meeting. Allergy Asthma Proc 27:254-264, 2006.
43. Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhìnitis. Allergy Asthma Proc 28:145-152, 2007.
44. Gonyeau MJ, and Partisano AM. A clinical review of monte-lukast in the treatment of seasonal allergic rhinitis. Formulary 38:368-378, 2003.
45. Meltzer EO, Malstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 105:917-922, 2000.
46. Juniper EF, Kline PA, Hargreave EF, and Dolovich J. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 83:627-633, 1989.
47. Ratner PH, van Bavel JH, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 47:118-125, 1998.
48. Barnes ML, Ward JH, Fardon TC, et al. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy 36:676-684, 2006.
49. Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast, and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 34:259-267, 2004.
50. Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:74-81, 2008.
51. Purello-D'Ambrosio F, Isola S, Ricciardi L, et al. A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosino-philia (NARES). Clin Exp Allergy 29:1143-1147, 1999.
52. Canonica GW, and Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 111:437-448, 2003.
53. Aurora J. Development of nasal delivery systems: A review. Drug Delivery Technol 2:70-73, 2002.
54. Bachert C, and El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 89:292-297, 2002.
55. Shah SR, Miller C, Pethick N, et al. Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray. Clin Ther 25:2198-2214, 2003.
56. Benninger MS, Hadley JA, and Osguthorpe JD. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg 130:5-24, 2004.
57. Allegra (fexofenadine) prescribing information. In Physicians' Desk Reference. Montvale, NJ: Thomson, Inc., 2007.
58. Claritin (loratadine) prescribing information. In Physicians' Desk Reference. Montvale, NJ: Thomson, Inc., 2007.
59. Zyrtec (cetirizine HC1) prescribing information. In Physicians' Desk Reference. Montvale, NJ: Thomson, Inc., 2007.
60. Clarinex (desloratadine) prescribing information. Kenilworth, NJ: Schering Corp; Rev February 2007.
61. Xyzal(levocetirizine) prescribing information. Bridgewater, NJ: Sanofi-Aventis US; Rev January 2008.